Drug treatment intensifications were performed in 9 patients: new or additional oral antidiabetic drug (OAD) or Glucagon-like peptide 1 receptor agonist (GLP1-RA) in 3 patients, increase of OAD dose (n = 1), increase of insulin dose in 4 patients (n = 3 in T2D, n = 1 in T1D), additional OAD plus increase of insulin dose (n = 1). This evidence concerns the gene INS and type 2 diabetes mellitus.